FDA Grants Priority Review to Zydus Therapeutics’ Saroglitazar for Rare Liver Disease
PENNINGTON, New Jersey and AHMEDABAD, India, May 28, 2026 Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, has...
Liver Disease
Advertisement
Brii Bio Reports Positive ENSURE HBV Cure Study Results
DURHAM, N.C. and BEIJING, China, May 27, 2026 Brii Biosciences Limited (Brii Bio) has presented new late-breaking clinical and...
Gilead Reports Strong Long-Term Livdelzi PBC Data
FOSTER CITY, Calif., May 28, 2026 Gilead Sciences announced new interim findings from the ongoing Phase 3 ASSURE study...
Precision BioSciences Reveals Breakthrough HBV Data
DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...
MediciNova Completes Phase 2 MN-001 Trial in NAFLD
LA JOLLA, Calif., May 26, 2026 MediciNova announced the completion of the Last Patient Last Visit (LPLV) in its...
Advertisements
Assembly Bio Expands ABI-6250 Into Liver Diseases
SOUTH SAN FRANCISCO, Calif., May 22, 2026 Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its...
AbbVie Reports Strong Phase 3 Results for MAVIRET in Acute HCV
North Chicago, Illinois, USA – May 22, 2026 AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products...
FDA Grants Historic Approval to Gilead’s Hepcludex for HDV
Foster City, California, USA – May 21, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration...
Monopar ALXN1840 Shows Strong Wilson Disease Benefit
WILMETTE, Ill., May 19, 2026 Monopar Therapeutics announced the publication of new Phase 2 clinical trial data showing that...
ArteraAI Breast Gains FDA Clearance for Cancer Risk
SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...
Advertisement
